ADMA Biologics Faces Securities Fraud Investigations
Analysis based on 55 articles · First reported Mar 26, 2026 · Last updated Apr 17, 2026
The market is negatively impacted by the allegations against ADMA Biologics, leading to a significant drop in its stock price. This event highlights the risks associated with potential corporate misconduct and the role of investigative research firms in uncovering such issues, potentially increasing scrutiny on other companies.
ADMA Biologics is under investigation by law firms Pomerantz LLP and Bleichmar Fonti & Auld LLP for alleged securities fraud. These investigations stem from a report published by Culper Research on March 24, 2026, which accused ADMA Biologics of a 'channel stuffing scheme' and an 'undisclosed related party distributor' to artificially inflate its 2025 revenue growth. Culper Research estimated that without this alleged scheme, ADMA Biologics' revenues would have declined by 3% instead of the reported 20% growth. Following the Culper Research report, ADMA Biologics' stock price fell by 16.63% on March 24, 2026. Two days later, Cantor Fitzgerald downgraded ADMA Biologics, expressing disappointment with the company's response to the allegations, which led to a further 13.91% decline in stock price. The total decline over two trading days was approximately 29%.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard